DEPO-MEDROL 20 MG — DIN 01934325
METHYLPREDNISOLONE ACETATE : 20 MG · PFIZER CANADA ULC · SUSPENSION · wholesale supply in Canada
Health Canada status: MARKETED
What is DEPO-MEDROL?
DEPO-MEDROL 20 MG contains METHYLPREDNISOLONE ACETATE : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 01934325, held by PFIZER CANADA ULC, supplied as SUSPENSION for INTRASYNOVIAL ; INTRA-ARTICULAR ; INTRAMUSCULAR ; INTRALESIONAL administration. Health Canada currently lists it as marketed, status dated 03-May-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DEPO-MEDROL used for?
Endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, GI, respiratory, hematologic, and neoplastic diseases. Used IM, intra-articularly, intrasynovially, or intralesionally.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Methylprednisolone cost around the world?
Methylprednisolone is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Morocco publishes a PPV (public price). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 9 | 61 | AUD███.██ |
| United States | acquisition | 8 | 32 | USD███.██ |
| Morocco | PPV (public price) | 5 | 18 | MAD███.██ |
| Saudi Arabia | public | 14 | 18 | SAR███.██ |
| South Africa | single exit price | 12 | 17 | ZAR███.██ |
| Greece | producer price (ex-factory) | 13 | 13 | EUR███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
160 pack listings across 62 brand entries and 6 price bases, refreshed 08 Sep 2026. Ranges span every Methylprednisolone pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Methylprednisolone in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Methylprednisolone, across 34 DINs, of which 13 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 19 | 13 | DEPO-MEDROL, MEDROL, SOLU-MEDROL | Sourceable in Canada |
| TEVA CANADA LIMITED | 5 | 0 | METHYLPREDNISOLONE SODIUM SUCCINATE FOR INJECTION | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 4 | 0 | METHYLPREDNISOLONE ACETATE INJECTABLE SUSPENSION USP, METHYLPREDNISOLONE ACETATE INJECTABLE SUSPENSION USP -(80MG/ML WITH PRESERVATIVE), METHYLPREDNISOLONE ACETATE INJECTABLE SUSPENSION USP -(40MG/ML WITH PRESERVATIVE) | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 2 | 0 | METHYLPREDNISOLONE SODIUM SUCCINATE FOR INJECTION, USP | No marketed DIN |
| TARO PHARMACEUTICALS INC | 2 | 0 | TARO-METHYLPREDNISOLONE INJECTION | No marketed DIN |
| THE UPJOHN COMPANY OF CANADA | 2 | 0 | SOLUMEDROL INJ 125MG STERILE MIXOVIAL, SOLUMEDROL INJ 40MG STERILE MIXOVIAL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 20 MG |
|---|---|
| Dosage form | SUSPENSION |
| Route | INTRASYNOVIAL ; INTRA-ARTICULAR ; INTRAMUSCULAR ; INTRALESIONAL |
| Pack configuration (monograph) | Benzyl alcohol formula: 20 mg/mL (5 mL), 40 mg/mL (2 & 5 mL), 80 mg/mL (5 mL). MGPC formula: 40 mg/mL (1 mL), 80 mg/mL (1 mL). |
| Storage | Not explicitly stated in provided text (standard practice is 15-30°C, but section 11 was not fully included). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Methylprednisolone |
|---|---|
| ATC code | H02AB04 |
| AHFS class | 68:04.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 01934325 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1934325 |
| Brand name | DEPO-MEDROL |
| Generic / active ingredient | METHYLPREDNISOLONE ACETATE : 20 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | H02AB04 |
| ATC anatomical main group | H — Systemic hormonal preparations |
| ATC therapeutic subgroup | H02AB |
| Current status | MARKETED |
| Status date | 03-May-2006 |
| Original market date | 1995-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Dosage varies by condition and route. Intra-articular: 4-80 mg based on joint size. IM: 40-120 mg. Intralesional: 20-60 mg. Must be individualized and decreased gradually.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; systemic fungal infections; IM use in idiopathic thrombocytopenic purpura; live vaccines; herpes simplex of the eye; vaccinia/varicella; epidural/intrathecal/intravascular use.
Warnings and precautions
Risk of HPA axis suppression; serious events with unauthorized routes; potential toxicity of benzyl alcohol to neural tissue; risk of Kaposi’s sarcoma; caution in CHF and hypertension.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
13 of 34 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| DEPO-MEDROL | 40 MG | SUSPENSION | PFIZER CANADA ULC | MARKETED | 01934333 |
| DEPO-MEDROL | 40 MG | SUSPENSION | PFIZER CANADA ULC | MARKETED | 00030759 |
| DEPO-MEDROL | 80 MG | SUSPENSION | PFIZER CANADA ULC | MARKETED | 01934341 |
| DEPO-MEDROL | 80 MG | SUSPENSION | PFIZER CANADA ULC | MARKETED | 00030767 |
| MEDROL | 4 MG | TABLET | PFIZER CANADA ULC | MARKETED | 00030988 |
| MEDROL | 16 MG | TABLET | PFIZER CANADA ULC | MARKETED | 00036129 |
| SOLU-MEDROL | 500 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 00030678 |
| SOLU-MEDROL | 1 G | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 00036137 |
| SOLU-MEDROL | 40 MG | KIT ; POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | 02367947 |
| SOLU-MEDROL | 125 MG | POWDER FOR SOLUTION ; KIT | PFIZER CANADA ULC | MARKETED | 02367955 |
2 · Same class — other molecules in ATC H02AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Dexamethasone | APO-DEXAMETHASONE · DECADRON PHOSPHATE INJ 4MG/ML · DECADRON TAB 0.5MG · DECADRON TAB 4MG · +24 more | 42 | 13 | Yes |
| Methylprednisolone | DEPO-MEDROL · MEDROL · METHYLPREDNISOLONE ACETATE INJECTABLE SUSPENSION USP · METHYLPREDNISOLONE ACETATE INJECTABLE SUSPENSION USP -(80MG/ML WITH PRESERVATIVE) · +7 more | 34 | 13 | Yes |
| Hydrocortisone | A-HYDROCORT INJ 1000MG/8ML · A-HYDROCORT INJ 100MG/2ML · A-HYDROCORT INJ 250MG/2ML · A-HYDROCORT INJ 500MG/4ML · +6 more | 18 | 8 | Yes |
| Prednisone | ALTI-PREDNISONE TAB 5MG · APO PREDNISONE TAB 1MG USP · APO PREDNISONE TAB 50MG · APO PREDNISONE TAB 5MG · +11 more | 19 | 5 | Yes |
| Triamcinolone | ARISTOCORT - SYR ORL 0.4MG/ML · ARISTOCORT - TAB 4MG · ARISTOCORT FORTE - LIQ IA IM ISY 40MG/ML · ARISTOCORT FORTE INJ 40MG/ML · +15 more | 21 | 3 | Yes |
| Betamethasone | BETAJECT · BETNESOL TAB 0.5MG · BETNESOL TABLETS · CELESTONE REPETABS 1MG · +2 more | 6 | 1 | Yes |
| Prednisolone | NOVO-PREDNISOLONE 5MG · PEDIAPRED · PEDIAPRED - LIQ 6.7MG/5ML · PMS-PREDNISOLONE | 4 | 1 | Yes |
| Cortisone | CORTISONE ACETATE · CORTONE SUS 50MG/ML · CORTONE TAB 25MG · CORTONE TAB 5MG | 4 | 1 | Yes |
| Prednisone, Combinations | METRETON TAB | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC H02A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| H02AA | Fludrocortisone | 3 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is DEPO-MEDROL called?
Also recorded in Canada as: methylprednisolone acetate 0.01 MG/MG Topical Gel [HybriSil] (US), methylprednisolone acetate 20 MG/ML Injectable Suspension [Depo-Medrol] (US), methylprednisolone acetate 40 MG/ML Injectable Suspension [Depo-Medrol] (US), methylprednisolone acetate 80 MG/ML Injectable Suspension [Depo-Medrol] (US), 1 ML methylprednisolone acetate 40 MG/ML Injection [Depo-Medrol] (US), 1 ML methylprednisolone acetate 80 MG/ML Injection [Depo-Medrol] (US), methylprednisolone acetate 0.01 MG/MG Topical Gel (US), lidocaine hydrochloride 10 MG/ML / methylprednisolone acetate 40 MG/ML Injectable Suspension (US), methylprednisolone acetate 20 MG/ML Injectable Suspension (US), methylprednisolone acetate 40 MG/ML Injectable Suspension (US), methylprednisolone acetate 80 MG/ML Injectable Suspension (US), 1 ML methylprednisolone acetate 40 MG/ML Injection (US), 1 ML methylprednisolone acetate 80 MG/ML Injection (US), METHYLPREDNISOLONE ACETATE (US), METHYLPREDNISOLONE ACETATE, BUPIVACAINE HYDROCHLORIDE, POVIDONE-IODINE (US).
The same molecule, Methylprednisolone, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Advantan | Latin | Australia |
| METHYLPREDNISOLONE MYLAN | Latin | Morocco |
| Advantan (Fatty) | Latin | Australia |
| Metvant | Latin | Australia |
| Metvant (Fatty) | Latin | Australia |
| Supriad Cream | Latin | Australia |
| Supriad Fatty Ointment | Latin | Australia |
| Supriad Ointment | Latin | Australia |
| Tanilone (Fatty) | Latin | Australia |
| SOLU MEDROL | Latin | Morocco |
| MEDROL | Latin | Morocco |
| Ap Methylpred | Latin | South Africa |
| DEPO MEDROL | Latin | Morocco |
| Medrolone | Latin | Saudi Arabia |
| METILBETASONE | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.